Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Earnings for Allena Pharmaceuticals, Inc. (ALNAQ)
Earnings in 2021 (TTM): $-32,845,000
According to Allena Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-32,845,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Allena Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2021 | $-32,845,000 | $-33,355,000 |
| 2020 | $-32,845,000 | $-32,845,000 |
| 2019 | $-47,339,000 | $-47,339,000 |
| 2018 | $-35,648,000 | $-35,648,000 |
| 2017 | $-21,650,000 | $-21,650,000 |
| 2016 | $-24,507,000 | $-24,507,000 |
| 2015 | $-14,247,000 | $-14,247,000 |